- call +1-201-465-4211
- email sales@mrinsights.biz
Peripheral artery disease (PAD) is a narrowing of the arteries other than those that supply the heart or the brain. When narrowing occurs in the heart, it is called coronary artery disease, while, in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication. Other symptoms including skin ulcers, bluish skin, cold skin, or poor nail and hair growth may occur in the affected leg. Complications may include an infection or tissue death which may require amputation; coronary artery disease, or stroke.[3] Up to 50% of cases of PAD are without symptoms.
Scope of the Report:
This report studies the Peripheral Arterial Disease (PAD) Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Peripheral Arterial Disease (PAD) Therapeutics market by product type and applications/end industries.
The global Peripheral Arterial Disease (PAD) Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Peripheral Arterial Disease (PAD) Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others
Market Segment by Applications, can be divided into
Hospitals
Clinics
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Peripheral Arterial Disease (PAD) Therapeutics Market Overview
1.1 Product Overview and Scope of Peripheral Arterial Disease (PAD) Therapeutics
1.2 Classification of Peripheral Arterial Disease (PAD) Therapeutics by Types
1.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Types in 2017
1.2.3 Anti-Platelet Drugs
1.2.4 Dual Antiplatelet Therapy Drugs
1.2.5 Others
1.3 Global Peripheral Arterial Disease (PAD) Therapeutics Market by Application
1.3.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Peripheral Arterial Disease (PAD) Therapeutics Market by Regions
1.4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Peripheral Arterial Disease (PAD) Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Peripheral Arterial Disease (PAD) Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Peripheral Arterial Disease (PAD) Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Peripheral Arterial Disease (PAD) Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Peripheral Arterial Disease (PAD) Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Peripheral Arterial Disease (PAD) Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 AstraZeneca Plc. (UK)
2.1.1 Business Overview
2.1.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Bayer HealthCare Pharmaceuticals (Germany)
2.2.1 Business Overview
2.2.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bristol-Myers Squibb Company (US)
2.3.1 Business Overview
2.3.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck & Co., Inc. (US)
2.4.1 Business Overview
2.4.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Proteon Therapeutics, Inc. (US)
2.5.1 Business Overview
2.5.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Sanofi S.A. (France)
2.6.1 Business Overview
2.6.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Symic Bio, Inc. (US)
2.7.1 Business Overview
2.7.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 TheraVasc Inc. (US)
2.8.1 Business Overview
2.8.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 AnGes MG, Inc. (Japan)
2.9.1 Business Overview
2.9.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Athersys, Inc. (US)
2.10.1 Business Overview
2.10.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.11 Betagenon AB (Sweden)
2.11.1 Business Overview
2.11.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.12 miRagen Therapeutics, Inc. (US)
2.12.1 Business Overview
2.12.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.13 Multi Gene Vascular Systems Ltd (Israel)
2.13.1 Business Overview
2.13.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.14 ViroMed Co. Ltd. (Korea)
2.14.1 Business Overview
2.14.2 Peripheral Arterial Disease (PAD) Therapeutics Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Peripheral Arterial Disease (PAD) Therapeutics Market Competition, by Players
3.1 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Peripheral Arterial Disease (PAD) Therapeutics Players Market Share
3.2.2 Top 10 Peripheral Arterial Disease (PAD) Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Regions
4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue and Market Share by Regions
4.2 North America Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Countries
5.1 North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Countries (2013-2018)
5.2 USA Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Countries
6.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Countries
7.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Countries (2013-2018)
7.2 China Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Countries
8.1 South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Peripheral Arterial Disease (PAD) Therapeutics by Countries
9.1 Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Peripheral Arterial Disease (PAD) Therapeutics Market Segment by Type
10.1 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Forecast by Type (2018-2023)
10.3 Anti-Platelet Drugs Revenue Growth Rate (2013-2023)
10.4 Dual Antiplatelet Therapy Drugs Revenue Growth Rate (2013-2023)
10.5 Others Revenue Growth Rate (2013-2023)
11 Global Peripheral Arterial Disease (PAD) Therapeutics Market Segment by Application
11.1 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Peripheral Arterial Disease (PAD) Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Others Revenue Growth (2013-2018)
12 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Forecast (2018-2023)
12.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Forecast (2018-2023)
12.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Peripheral Arterial Disease (PAD) Therapeutics Picture
Table Product Specifications of Peripheral Arterial Disease (PAD) Therapeutics
Table Global Peripheral Arteria
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
